<DOC>
	<DOCNO>NCT03073967</DOCNO>
	<brief_summary>Randomized , open-label , multi-center , comparative trial ass efficacy safety immunocompromised subject acyclovir resistant mucocutaneous HSV infection , treat pritelivir 100 mg qd ( follow load dose 400 mg first dose rapidly reach steady-state plasma concentration ) foscarnet 40 mg/kg iv tid/60mg/kg iv bid .</brief_summary>
	<brief_title>Trial Efficacy Safety Pritelivir Tablets Treatment Acyclovir-resistant Mucocutaneous HSV ( Herpes Simplex Virus ) Infections Immunocompromised Adults</brief_title>
	<detailed_description>Immunocompromised male female subject acyclovir-resistant mucocutaneous HSV infection base clinical failure require switch foscarnet treatment . The acyclovir resistance status document genotypic testing , result genotypic test negative inconclusive phenotypic test perform . Pritelivir trial medication give orally single daily dose 7 day mucocutaneous HSV lesion heal maximum 28 day , whichever early . Foscarnet give intermittent infusion dose 40 mg/kg every 8 hour 60mg/kg every 12 hour ( adjusted case renal impairment ) minimum 1 hour duration 7 day mucocutaneous HSV lesion heal maximum 28 day , whichever early .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>1 . Immunocompromised men woman ethnic group age ≥18 year . 2 . Acyclovir resistant mucocutaneous HSV infection base clinical failure require switch foscarnet treatment . 3 . Lesion accessible size measurement photography . 4 . Willingness abstain application lotion and/or creams area HSV lesion . 5 . Ability swallow tablet . 6 . Willing use nonhormonal birth control : Male subject surgically sterile ( eg , vasectomy ) must agree use adequate method contraception participation trial least 1 complete month final dose trial medication . Female subject surgically sterile ( eg , 2sided tubal ligation , resection ovariectomy , hysterectomy ) postmenopausal ( define least 50 year age history menses least 24 month ) female subject childbearing potential male partner , use adequate method contraception participation trial least 1 complete month final dose trial medication . An adequate method contraception define one follow acceptable birth control method : use copperreleasing intrauterine device ( place least 2 month prior screen ) use one following : diaphragm , Lea 's shield , FemCap , sponge , monogamous relationship vasectomize partner use male condom act sexual intercourse . 7 . Subject must willing able ( opinion investigator ) understand inform consent form 8 . Negative serum β HCG ( beta human chorionic gonadotropin ) test female child bear potential screening negative urine pregnancy test randomization . 9 . Subject must give write informed consent . 1 . Known intolerance pritelivir and/or foscarnet excipients . 2 . Need use drug narrow therapeutic index substrate CYP2B6 , CYP2C8 , CYP2C9 , CYP2C19 , OATP1B1 , OATP1B3 , OCT1 ( organic cation transporter 1 ) , ie warfarin , digoxin , phenytoin , paclitaxel , Smephenytoin 3 . Baseline safety laboratory abnormality : ANC ( absolute neutrophil Count ) &lt; 1000 cells/mm3 , platelet count &lt; 25,000 cells/mm3 , hemoglobin &lt; 8.0 g/dL , AST ( aspartate transaminase ) ALT ( alanine transaminase ) &gt; 5 x ULN ( upper Limit normal ) , bilirubin &gt; 2.5 x ULN 4 . History current evidence gastrointestinal malabsorption , opinion investigator , may affect extent absorption pritelivir . 5 . Severe renal insufficiency ( GFR ≤ 29 ) . 6 . History current evidence significant cardiovascular , pulmonary , hepatic , renal , gastrointestinal , hematological , endocrinological , metabolic , neurological , psychiatric , disease , , opinion investigator , may affect subject 's safety interfere trial . 7 . Abnormalities hematological , clinical chemical laboratory variable Screening measured central local laboratory regard clinically relevant investigator unless due underlie disease condition . 8 . Not able communicate meaningfully Investigator site staff . 9 . Any condition opinion investigator would interfere successful completion clinical trial . 10 . Any local condition include bacterial superinfection opinion investigator would interfere efficacy evaluation . 11 . Pregnant and/or breastfeed woman . 12 . Participation investigational drug trial within last 30 day randomization clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>